ACVR1 and neoplasm: First, scientists need to know when this pathway behaves as pro- or anti-angiogenic and this different behavior seems to be related to the heterogeneity of tumor blood vessels and the composition of BMPRI (ALK1, ALK2, ALK3 and ALK6) and BMPRII receptors.